Bristol-Myers clobbered—shares drop 17%—after failed drug test – CNBC


CNBC
Bristol-Myers clobbered—shares drop 17%—after failed drug test
CNBC
Shares of Bristol-Myers Squibb plunged more than 17 percent in morning trading Friday after its important cancer drug failed to meet targets in a late-stage study. Shares of Bristol-Myers’ competitors who have their own versions of the cancer therapy
Bristol-Myers’ Opdivo fails lung cancer trial; shares plungeReuters
Bristol-Myers drug fails lung cancer study, shares plungeU.S. News & World Report
Bristol-Myers Squibb Statement on Top-Line Results from CheckMate -026 | BMS NewsroomBMS – Bristol-Myers Squibb

all 162 news articles >>

Source: shares – Google News

Sharing information is key – Share Dealing Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd